Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease.

Author: BednarskiRafał, DonderskiRafał, HeleniakZbigniew, LizakowskiSławomir, ManitiusJacek, PrzybylskaMilena, RenkeMarcin, RutkowskiBolesław, RutkowskiPrzemysław, SulikowskaBeata, TylickiLeszek

Paper Details 
Original Abstract of the Article :
Various methods of combination renin-angiotensin-aldosterone system blockade help achieve more potent antiproteinuric effects, but may be associated with higher risk of side effects. Therapies involving direct renin inhibitor, aliskiren, may promote renal fibrosis by stimulating (pro)renin receptor ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.20452/pamw.1726

データ提供:米国国立医学図書館(NLM)

The Safety of Enhanced Renin-Angiotensin-Aldosterone System Inhibition in Chronic Kidney Disease

Chronic kidney disease (CKD) can be as challenging to manage as a desert ecosystem, requiring a delicate balance to maintain stability. This study investigates the safety of enhancing renin-angiotensin-aldosterone system (RAAS) inhibition with aliskiren in nondiabetic patients with CKD, exploring the potential risks and benefits of this therapeutic approach. The authors examine the potential for aliskiren to stimulate the (pro)renin receptor, a mechanism that could potentially contribute to renal fibrosis, a condition as damaging as a desert sandstorm eroding a fragile landscape.

Balancing Benefits and Risks

The study highlights the need to carefully balance the potential benefits and risks of enhanced RAAS inhibition in CKD patients. This approach, like a desert nomad carefully navigating treacherous terrain, requires a thorough understanding of the potential consequences of each step taken. While RAAS inhibition can be beneficial for reducing proteinuria, the study emphasizes the importance of monitoring for potential adverse effects, particularly renal fibrosis.

Further Research Needed

The study underscores the need for further research to fully understand the long-term safety of enhanced RAAS inhibition in CKD patients. This knowledge is like a reliable map guiding us through the complex landscape of CKD management. The study highlights the importance of continued research to optimize treatment strategies and ensure the best possible outcomes for patients with this chronic condition.

Dr. Camel’s Conclusion

This research underscores the importance of careful consideration when it comes to managing CKD. The study emphasizes the need for vigilance in monitoring potential risks and benefits of RAAS inhibition, reminding us that navigating this challenging condition requires a balanced approach, much like a desert nomad seeking equilibrium amidst the harsh realities of the environment.

Date :
  1. Date Completed 2015-04-13
  2. Date Revised 2019-11-12
Further Info :

Pubmed ID

23615633

DOI: Digital Object Identifier

10.20452/pamw.1726

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.